Q1 2026 Alembic Pharmaceuticals Ltd Earnings Call Transcript
Key Points
- Alembic Pharmaceuticals Ltd (BOM:533573) reported a 10% year-on-year increase in total revenue for Q1 FY26, reaching INR1,711 crores.
- Gross margin improved from 74.8% to 76.2% year-on-year, driven by a favorable product mix and cost improvement programs.
- EBITDA margins before R&D expenses increased to 25% of revenue, reflecting a 23% growth over the previous year.
- The international business, particularly the US market, showed strong performance with a 13% growth supported by volume gains and new product launches.
- The company successfully launched four products in the US market and expects further growth with upcoming launches in the next quarters.
- The India branded business underperformed with only a 5% year-on-year growth, facing challenges in execution and market inventory management.
- R&D expenses increased by 26% compared to the previous year, impacting overall profitability.
- The API business remained flat due to data availability issues in India and ongoing pricing pressures.
- There is ongoing pricing pressure in the US generics market, which could impact future profitability.
- The company faces challenges in achieving full execution across all districts in India, which may delay reaching double-digit growth in the domestic market.
Ladies and gentlemen, good day and welcome to Q1 FY26 earnings conference call of Alembic Pharmaceuticals Limited. We have with us today Mr. Pranav Amin, Managing Director; Mr. Shaunak Amin, Managing Director; Mr. R. K. Baheti, Executive Director; Mr. G. Krishnan, CFO; Mr. Ajay Kumar Desai, Senior Vice President, Finance.
As a reminder, this conference call is only for analysts, institutional investors. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. R. K. Baheti. Thank you, and over to you, sir.
Thank you. Thank you, everyone, for joining our first-quarter '26 conference call. I am very happy to introduce my colleague, Mr. G. Krishnan, who has joined us as our CFO effective July 7, 2025.
And I am pleased to hand it over to him for the opening remarks. Krishnan?
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
